Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Novartis
Novartis
Dana-Farber Cancer Institute
University of Liverpool
Ascentage Pharma Group Inc.
Australasian Leukaemia and Lymphoma Group
Astex Pharmaceuticals, Inc.
Italian Sarcoma Group
Rutgers, The State University of New Jersey
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Bristol-Myers Squibb
Rennes University Hospital
Asan Medical Center
M.D. Anderson Cancer Center
University of Washington
Samsung Medical Center
Gruppo Italiano Malattie EMatologiche dell'Adulto
Novartis
Novartis
Novartis
Mansoura University
Istituto Clinico Humanitas
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Yonsei University
National Cancer Institute (NCI)
Oslo University Hospital
University Health Network, Toronto
Gruppo Italiano Malattie EMatologiche dell'Adulto
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Novartis
AEterna Zentaris
OHSU Knight Cancer Institute
Norwegian University of Science and Technology
National Institutes of Health Clinical Center (CC)
Novartis
Novartis
National Cancer Institute (NCI)
Heidelberg University
University of Washington
Massachusetts General Hospital
Novartis
Novartis
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Novartis
Novartis
M.D. Anderson Cancer Center